Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis

Inclusion Criteria: * Male or female subjects 18 years of age or older. * Surgically sterile females. Females who have had a hysterectomy or completed menopause are allowed. * Affected Body Surface Area with psoriasis of ≥10%. * Psoriasis Global Assessment rating of "moderate to severe" or "severe". * Achieved mild to moderate improvement after receiving an injectable biologic therapy for at least 12 weeks. * A PASI score of ≥ 50 and ≤75 * Capable of understanding and willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements) before any protocol specific procedures are performed Exclusion Criteria: * Understand that the sponsor can not pay for the an injectable biologic therapy during the course of the study; be willing to pay out of pocket or secure payment through their private health insurance for an injectable biologic. * History of systemic infection, or other conditions that may interfere with study evaluations or may increase risk for participation. such as, tuberculosis, human immunodeficiency virus (HIV), hepatitis; congestive heart failure or demyelinating disorder. * Used of prohibited medications or therapies